VaxEquity
Chemicals & Related Products · United States · <25 Employees
View Company Info for Free
About
Headquarters
United StatesWebsite
www.vaxequity.comRevenue
<$5 MillionIndustry
Recent News & Media
Who is VaxEquity
VaxEquity is a biotechnology company amplifying the impact of RNA vaccines and therapeutics, through using its next generation self-amplifying RNA (saRNA) platform. The Company uses saRNA to provide greatly enhanced protein expression, combining better tolerability with slower release and thermostability. VaxEquity is pioneering a next generation approach by modifying its saRNA to modulate the immune response and thereby overcoming current limitations. The flexibility of the Companys platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale. VaxEquity was founded in 2020 by Professor Robin Shattock, the Head of Immunology of Infection at Imperial College London and is led by a world class team who are pioneers in the field of RNA.Read more
VaxEquity Org Chart
Is VaxEquity your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at VaxEquity
Funding: Get notified immidiatlly once VaxEquity has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when VaxEquity launches new products
Check out if VaxEquity is spiking on competitors!
Check if VaxEquity has recently received funding, and reach out quickly before it becomes old news!
Click to see if VaxEquity had a recent Job posting/layoffs
Earning: See what the market has to say on VaxEquity recently announced quarterly report
VaxEquity, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Similar Companies to VaxEquity
Analyze insights from companies similar to VaxEquity and make strategic comparisons based on performance, financial data, growth and unique benchmarks.
- The Column Group36
$7.6M - Pappas Ventures companies<25$5.5M
- Novartis Venture Fund<25<$5M
- Kslsf<25<$5M
- Digi Communications<25<$5M
- Dren Bio50$10.6M
- Prothix<25<$5M
- Immunomic Therapeutics41$5.3M
More similar companies
VaxEquity Employee Growth Rate
View VaxEquity’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
VaxEquity Tech Stack
A closer look at the technologies used by VaxEquity
See more technologies
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Most Recent Scoops
Last Week
Hot Scoop - Business
Last month
Hot Scoop - Financial
Last month
Hot Scoop - Opportunities
VaxEquity News & Media
VaxEquity and CPI Announces Innovate UK Grant to Accelerate Next Generation RNA Vaccines and Therapeutics
CAMBRIDGE, United Kingdom, June 05, 2023 (GLOBE NEWSWIRE) -- VaxEquity, developing transformative RNA vaccines and therapeutics based on its next generation self-amplifying RNA (saRNA) platform, and CPI, the UK’s leading independent technology innovation centre, today announce a grant of approximately £700K from Innovate UK. The grant will fund a collaborative project to advance the manufacturing process for RNA vaccines and therapeutics.
Read more news
Frequently Asked Questions Regarding VaxEquity
VaxEquity is a biotechnology company amplifying the impact of RNA vaccines and therapeutics, through using its next generation self-amplifying RNA (saRNA) platform. The Company uses saRNA to provide greatly enhanced protein expression, combining better tolerability with slower release and thermostability. VaxEquity is pioneering a next generation a... Read More
